Gentamicin, genetic variation and deafness in preterm children

BMC Pediatrics

Neil Marlow¹  Kathy Chant¹  Shamima Rahman²  Maria Bitner-Glindzicz² 

[1]Neonatology Department, University College London Institute for Women’s Health, Medical School Building, 74 Huntley Street, London WC1E 6 AU, UK

[2]Genetics and Genomic Medicine, University College London Institute of Child Health and Great Ormond Street Hospital for Children, 30 Guilford Street, London WC1N 1EH, UK

关键词: Prematurity;    Preterm;     G;    m.1555A >;    Mitochondrial;    Hearing loss;    Deafness;    Aminoglycosides;    Gentamicin;   

Others  :  1138966
DOI  :  10.1186/1471-2431-14-66

 received in 2014-01-27, accepted in 2014-02-26,  发布年份 2014

【 摘 要 】

Background

Hearing loss in children born before 32 weeks of gestation is more prevalent than in full term infants. Aminoglycoside antibiotics are routinely used to treat bacterial infections in babies on neonatal intensive care units. However, this type of medication can have harmful effects on the auditory system. In order to avoid this blood levels should be maintained in the therapeutic range. However in individuals with a mitochondrial genetic variant (m.1555A > G), permanent hearing loss can occur even when drug levels are within normal limits. The aim of the study is to investigate the burden that the m.1555A > G mutation represents to deafness in very preterm infants.

Method

This is a case control study of children born at less than 32 completed weeks of gestation with confirmed hearing loss. Children in the control group will be matched for sex, gestational age and neonatal intensive care unit on which they were treated, and will have normal hearing. Saliva samples will be taken from children in both groups; DNA will be extracted and tested for the mutation. Retrospective pharmacological data and clinical history will be abstracted from the medical notes. Risk associated with gentamicin, m.1555A > G and other co-morbid risk factors will be evaluated using conditional logistic regression.

Discussion

If there is an increased burden of hearing loss with m.1555A > G and aminoglycoside use, consideration will be given to genetic testing during pregnancy, postnatal testing prior to drug administration, or the use of an alternative first line antibiotic. Detailed perinatal data collection will also allow greater definition of the causal pathway of acquired hearing loss in very preterm children.

【 授权许可】

   
2014 Bitner-Glindzicz et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Lorenz JM, Wooliever DE, Jetton JR, Paneth N: A quantitative review of mortality and developmental disability in extremely premature newborns. Arch Pediatr Adolesc Med 1998, 152(5):425.
• [2]Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR: Neurologic and developmental disability after extremely preterm birth. N Engl J Med 2000, 343(6):378-384.
• [3]Roberts G, Anderson PJ, Doyle LW: Neurosensory disabilities at school age in geographic cohorts of extremely low birth weight children born between the 1970s and the 1990s. J Pediatr 2009, 154(6):829-834.
• [4]Marlow ES, Hunt LP, Marlow N: Sensorineural hearing loss and prematurity. Arch Dis Child Fetal Neonatal Ed 2000, 82(2):F141-F144.
• [5]Tharpe AM: Unilateral and mild bilateral hearing loss in children: past and current perspectives. Trends Amplif 2008, 12(1):7-15.
• [6]Cristobal R, Oghalai J: Hearing loss in children with very low birth weight: current review of epidemiology and pathophysiology. Arch Dis Child Fetal Neonatal Ed 2008, 93(6):F462-F468.
• [7]Vohr BR, Widen JE, Cone-Wesson B, Sininger YS, Gorga MP, Folsom RC, Norton SJ: Identification of neonatal hearing impairment: characteristics of infants in the neonatal intensive care unit and well-baby nursery. Ear Hear 2000, 21(5):373-382.
• [8]Yoshikawa S, Ikeda K, Kudo T, Kobayashi T: The effects of hypoxia, premature birth, infection, ototoxic drugs, circulatory system and congenital disease on neonatal hearing loss. Auris, nasus, larynx 2004, 31(4):361.
• [9]NICE Clinical Guideline 149: Antibiotics for early-onset neonatal infection. 2012. Available from: http://www.nice.org.uk/nicemedia/live/13867/60633/60633.pdf webcite
• [10]Rahman S, Ecob R, Costello H, Sweeney MG, Duncan AJ, Pearce K, Strachan D, Forge A, Davis A, Bitner-Glindzicz M: Hearing in 44–45 year olds with m. 1555A> G, a genetic mutation predisposing to aminoglycoside-induced deafness: a population based cohort study. BMJ open 2012, 2(1):1-8.
• [11]Estivill X, Govea N, Barcelo A, Perello E, Badenas C, Romero E, Moral L, Scozzari R, D’Urbano L, Zeviani M, Torroni A: Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides. Am J Hum Genet 1998, 62(1):27.
• [12]Bitner-Glindzicz M, Pembrey M, Duncan A, Heron J, Ring SM, Hall A, Rahman S: Prevalence of mitochondrial 1555A → G mutation in European children. N Engl J Med 2009, 360(6):640-642.
• [13]Guan M-X, Fischel-Ghodsian N, Attardi G: A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet 2000, 9(12):1787-1793.
• [14]Hutchin T, Cortopassi G: Proposed molecular and cellular mechanism for aminoglycoside ototoxicity. Antimicrob Agents Chemother 1994, 38(11):2517.
• [15]Bitner-Glindzicz M, Rahman S: Ototoxicity caused by aminoglycosides. BMJ 2007, 335(7624):784-785.